Evidence map›Paper›PMID 28487826›Full record

ArticleMolecular genetics and metabolism reports2017

Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels.

Bruna Donida, Desirèe P Marchetti, Carlos Eduardo Diaz Jacques, Graziela Ribas, Marion Deon, Paula Manini, Helen Tais da Rosa, Dinara Jaqueline Moura, Jenifer Saffi, Roberto Giugliani and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular genetics and metabolism reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Bruna DonidaPrograma de Pós-Graduação em Ciências Biológicas, Bioquímica, UFRGS, Porto Alegre, RS, Brazil.
Desirèe P MarchettiPrograma de Pós-Graduação em Ciências Biológicas, Bioquímica, UFRGS, Porto Alegre, RS, Brazil.
Carlos Eduardo Diaz JacquesPrograma de Pós-Graduação em Ciências Biológicas, Bioquímica, UFRGS, Porto Alegre, RS, Brazil.
Graziela RibasPrograma de Pós Graduação em Saúde da Criança e do Adolescente, UFRGS, Porto Alegre, RS, Brazil.
Marion DeonPrograma de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Porto Alegre, RS, Brazil.
Paula ManiniLaboratório de Genética Toxicológica, UFCSPA, Porto Alegre, RS, Brazil.
Helen Tais da RosaPrograma de Pós-Graduação em Ciências Biológicas, Bioquímica, UFRGS, Porto Alegre, RS, Brazil.
Dinara Jaqueline MouraLaboratório de Genética Toxicológica, UFCSPA, Porto Alegre, RS, Brazil.
Jenifer SaffiLaboratório de Genética Toxicológica, UFCSPA, Porto Alegre, RS, Brazil.
Roberto GiuglianiServiço de Genética Médica, HCPA, Porto Alegre, RS, Brazil.
Carmen Regla VargasPrograma de Pós-Graduação em Ciências Biológicas, Bioquímica, UFRGS, Porto Alegre, RS, Brazil.
Universidade Federal do Rio Grande do Sul · BRUniversidade Federal de Ciências da Saúde de Porto Alegre · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Morquio A disease (Mucopolysaccharidosis type IVA, MPS IVA) is one of the 11 mucopolysaccharidoses (MPSs), a heterogeneous group of inherited lysosomal storage disorders (LSDs) caused by deficiency in enzymes need to degrade glycosaminoglycans (GAGs). Morquio A is characterized by a decrease in

Indexed as

8-OHdG, 8-hydroxy-2′-deoxyguanosineCr, creatinineDI, damage indexDTNB, 5,5′-dithiobis(2-nitrobenzoic acid)ELISA, enzyme-linked immunoassayEndo III, endonuclease IIIERT, enzyme replacement therapyFU, fluorescence unitsGAGs, glycosaminoglycansGALNS, N-acetylgalactosamine-6-sulfataseGCLC, catalytic subunit of GCLGCL, glutamate cysteine ligaseGPx, glutathione peroxidaseGR, glutathione reductaseGSH, reduced glutathioneGSSG, glutathione oxidizedH2O2, hydrogen peroxideIEM, inborn errors of metabolismKeratan sulfateLPS, lipopolysaccharideLSDs, lysosomal storage disordersMorquio A syndromeMPSs, mucopolysaccharidosesmRNA, messenger ribonucleic acidMucopolysaccharidosis type IVAN-acetyl-galactosamine-6-sulfataseOH•, hydroxyl radicalOxidative stressROS, reactive oxygen speciesSEM, standard error of the meanSOD, superoxide dismutaseTLR4, Toll Like Receptor 4TNB, tionitrobenzoic acid

Identifiers

PMID28487826
PMCPMC5408501
OpenAlexW2609672502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.